Prostaglandin F2a tris salt cas no:38562-01-5
Synonyms: 2-amino-2-(hydroxymethyl)propane-1,3-diol; (E)-7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid;Panacelan F tromethamine salt;Enzaprost F compd. with trisamine;Dinoprost tromethamine (JAN/USP);Prostaglandin F2.alpha., compd. with 2-amino-2-hydroxymethyl-1,3-propanediol (1:1);Dinoprost tromethamine;7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid, tromethamine salt;Prosta-5,13-dien-1-oic acid, (5Z,9.alpha.,11.alpha.,13E,15S)-9,11,15-trihydroxy- compd. with (trimethylolamino)methane;Prosta-5,13-dien-1-oic acid, 9,11, 15-trihydroxy-, (5Z,9.alpha.,11.alpha.,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1);Ensaprost;Pronalgon F;Prosta-5,13-dien-1-oic acid,9,11,15-trihydroxy-,(5Z,9R,11R,13E,- 15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1);Zinoprost;Dinoprost Trometamol;
NameProstaglandin F2a tris salt
CAS38562-01-5
Synonyms2-amino-2-(hydroxymethyl)propane-1,3-diol; (E)-7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid;Panacelan F tromethamine salt;Enzaprost F compd. with trisamine;Dinoprost tromethamine (JAN/USP);Prostaglandin F2.alpha., compd. with 2-amino-2-hydroxymethyl-1,3-propanediol (1:1);Dinoprost tromethamine;7-[3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid, tromethamine salt;Prosta-5,13-dien-1-oic acid, (5Z,9.alpha.,11.alpha.,13E,15S)-9,11,15-trihydroxy- compd. with (trimethylolamino)methane;Prosta-5,13-dien-1-oic acid, 9,11, 15-trihydroxy-, (5Z,9.alpha.,11.alpha.,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1);Ensaprost;Pronalgon F;Prosta-5,13-dien-1-oic acid,9,11,15-trihydroxy-,(5Z,9R,11R,13E,- 15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1);Zinoprost;Dinoprost Trometamol;
EINECS(EC#)254-002-3
Molecular FormulaC20H34O5.C4H11NO3
Molecular Weight475.616
storage temp−20°C
Hazard T: Toxic;
Risk R60;R22
Safety
Poison by intraperitoneal, subcutaneous, intravenous, and intramuscular routes. Moderately toxic by ingestion. Human reproductive effects by intervaginal route: terminates pregnancy, effects on fertility. Experimental teratogenic and reproductive effects. When heated to decomposition it emits toxic fumes of NOx. See also PROSTAGLANDIN A1; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROSTAGLANDIN E2 SODIUM SALT; PROSTAGLANDIN F1-α; PROSTAGLANDIN F2-α; dl-PROSTAGLANDIN F2-α.
Hazard Codes of Prostaglandin F2a tris salt (CAS NO.38562-01-5): 
T
Risk Statements:
R22:Harmful if swallowed.
R60:May impair fertility.
Safety Statements:
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S53:Avoid exposure - obtain special instructions before use.
| Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
| mouse |
LD50 |
intramuscular |
111mg/kg (111mg/kg) |
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 623, 1974. |
| mouse |
LD50 |
intraperitoneal |
101mg/kg (101mg/kg) |
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 623, 1974. |
| mouse |
LD50 |
intravenous |
331mg/kg (331mg/kg) |
|
Drugs in Japan Vol. 6, Pg. 327, 1982. |
| mouse |
LD50 |
oral |
711mg/kg (711mg/kg) |
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 623, 1974. |
| mouse |
LD50 |
subcutaneous |
214mg/kg (214mg/kg) |
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 623, 1974. |
| rat |
LD50 |
intramuscular |
59mg/kg (59mg/kg) |
|
Drugs in Japan Vol. 6, Pg. 327, 1982. |
| rat |
LD50 |
intraperitoneal |
101mg/kg (101mg/kg) |
|
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 22, Pg. 517, 1975. |
| rat |
LD50 |
intravenous |
101mg/kg (101mg/kg) |
|
Drugs in Japan Vol. 6, Pg. 327, 1982. |
| rat |
LD50 |
oral |
665mg/kg (665mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
SKIN AND APPENDAGES (SKIN): HAIR: OTHER |
Yakkyoku. Pharmacy. Vol. 32, Pg. 1129, 1981. |
| rat |
LD50 |
subcutaneous |
66mg/kg (66mg/kg) |
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION |
Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 21, Pg. 623, 1974. |
